These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 2877832

  • 41. The disposition of the new anthracycline antibiotic, menogarol, in mice.
    Dodion P, Chang BK, Egorin MJ, Olman EA, Engisch KL, Bachur NR.
    Drug Metab Dispos; 1984; 12(3):365-70. PubMed ID: 6145565
    [Abstract] [Full Text] [Related]

  • 42. Teratogenicity of N-(4-hydroxyphenyl)-all-trans-retinamide in rats and rabbits.
    Kenel MF, Krayer JH, Merz EA, Pritchard JF.
    Teratog Carcinog Mutagen; 1988; 8(1):1-11. PubMed ID: 2897720
    [Abstract] [Full Text] [Related]

  • 43. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA.
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [Abstract] [Full Text] [Related]

  • 44. Inhibition of mammary tumorigenesis in nulliparous C3H mice by chronic feeding of the synthetic retinoid, N-(4-hydroxyphenyl)-retinamide.
    Welsch CW, DeHoog JV, Moon RC.
    Carcinogenesis; 1983 Sep; 4(9):1185-7. PubMed ID: 6224605
    [Abstract] [Full Text] [Related]

  • 45. Metabolism of N-[4-hydroxyphenyl]retinamide (4-HPR) to N-[4-methoxyphenyl]retinamide (4-MPR) may serve as a biomarker for its efficacy against human breast cancer and melanoma cells.
    Mehta RR, Hawthorne ME, Graves JM, Mehta RG.
    Eur J Cancer; 1998 May; 34(6):902-7. PubMed ID: 9797705
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Biotransformation and protein binding of N-(4-hydroxyphenyl)retinamide in murine mammary epithelial cells.
    Bunk MJ, Kinahan JJ, Sarkar NH.
    Cancer Lett; 1985 Apr; 26(3):319-26. PubMed ID: 2986832
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Therapeutic effect of N-(4-hydroxyphenyl)retinamide on N-methyl-N-nitrosourea-induced rat mammary cancer.
    Dowlatshahi K, Mehta RG, Thomas CF, Dinger NM, Moon RC.
    Cancer Lett; 1989 Oct; 47(3):187-92. PubMed ID: 2534548
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Retinoid-tamoxifen interaction in mammary cancer chemoprevention.
    McCormick DL, Moon RC.
    Carcinogenesis; 1986 Feb; 7(2):193-6. PubMed ID: 2936526
    [Abstract] [Full Text] [Related]

  • 57. In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences.
    Berni R, Formelli F.
    FEBS Lett; 1992 Aug 10; 308(1):43-5. PubMed ID: 1386578
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.